OBJECTIVE: The aim of this study was to examine if maternal plasma concentrations of soluble vascular endothelial growth factor receptor (sVEGFR)-2 change prior to the diagnosis of preeclampsia. STUDY DESIGN: A longitudinal study was conducted in normal pregnant women (n = 160) and patients with preeclampsia (n = 40). Blood samples were collected at 7 gestational age intervals from 6 weeks to term. Plasma concentrations of sVEGFR-2 were determined by enzyme-linked immunosorbent assay. Analysis was performed with cross-sectional and longitudinal (mixed effects model) approaches. RESULTS: Mothers destined to develop preeclampsia have lower plasma sVEGFR-2 concentrations than those who will have a normal pregnancy (longitudinal approach; P < .05). Cross-sectional analysis suggested that the median plasma sVEGFR-2 concentration in women destined to develop preeclampsia was significantly lower than that in normal pregnant women from 28-31 weeks of gestation (P = .001) or 6-10 weeks prior to the diagnosis (P < .001). CONCLUSION: A lower maternal plasma sVEGFR-2 concentration precedes the development of preeclampsia, both term and preterm. Copyright 2010 Mosby, Inc. All rights reserved.
OBJECTIVE: The aim of this study was to examine if maternal plasma concentrations of soluble vascular endothelial growth factor receptor (sVEGFR)-2 change prior to the diagnosis of preeclampsia. STUDY DESIGN: A longitudinal study was conducted in normal pregnant women (n = 160) and patients with preeclampsia (n = 40). Blood samples were collected at 7 gestational age intervals from 6 weeks to term. Plasma concentrations of sVEGFR-2 were determined by enzyme-linked immunosorbent assay. Analysis was performed with cross-sectional and longitudinal (mixed effects model) approaches. RESULTS: Mothers destined to develop preeclampsia have lower plasma sVEGFR-2 concentrations than those who will have a normal pregnancy (longitudinal approach; P < .05). Cross-sectional analysis suggested that the median plasma sVEGFR-2 concentration in women destined to develop preeclampsia was significantly lower than that in normal pregnant women from 28-31 weeks of gestation (P = .001) or 6-10 weeks prior to the diagnosis (P < .001). CONCLUSION: A lower maternal plasma sVEGFR-2 concentration precedes the development of preeclampsia, both term and preterm. Copyright 2010 Mosby, Inc. All rights reserved.
Authors: Jennifer F Tseng; Filip A Farnebo; Oliver Kisker; Christian M Becker; Calvin J Kuo; Judah Folkman; Richard C Mulligan Journal: Surgery Date: 2002-11 Impact factor: 3.982
Authors: D Scott McLeod; Makoto Taomoto; Jingtai Cao; Zhenping Zhu; Larry Witte; Gerard A Lutty Journal: Invest Ophthalmol Vis Sci Date: 2002-02 Impact factor: 4.799
Authors: Richard J Levine; Sharon E Maynard; Cong Qian; Kee-Hak Lim; Lucinda J England; Kai F Yu; Enrique F Schisterman; Ravi Thadhani; Benjamin P Sachs; Franklin H Epstein; Baha M Sibai; Vikas P Sukhatme; S Ananth Karumanchi Journal: N Engl J Med Date: 2004-02-05 Impact factor: 91.245
Authors: Christian M Becker; Filip A Farnebo; Irina Iordanescu; Danielle J Behonick; Mei-Chiung Shih; Patricia Dunning; Rolf Christofferson; Richard C Mulligan; George A Taylor; Calvin J Kuo; Bruce R Zetter Journal: Cancer Biol Ther Date: 2002 Sep-Oct Impact factor: 4.742
Authors: Tinnakorn Chaiworapongsa; Roberto Romero; Francesca Gotsch; Jimmy Espinoza; Jyh Kae Nien; Luis Goncalves; Samuel Edwin; Yeon Mee Kim; Offer Erez; Juan Pedro Kusanovic; Beth L Pineles; Zoltan Papp; Sonia Hassan Journal: J Matern Fetal Neonatal Med Date: 2008-01
Authors: Amy E Whitten; Roberto Romero; Steven J Korzeniewski; Adi L Tarca; Alyse G Schwartz; Lami Yeo; Zhong Dong; Sonia S Hassan; Tinnakorn Chaiworapongsa Journal: Am J Obstet Gynecol Date: 2013-01-17 Impact factor: 8.661
Authors: Tinnakorn Chaiworapongsa; Roberto Romero; Steven J Korzeniewski; Juan Pedro Kusanovic; Eleazar Soto; Jennifer Lam; Zhong Dong; Nandor G Than; Lami Yeo; Edgar Hernandez-Andrade; Agustín Conde-Agudelo; Sonia S Hassan Journal: Am J Obstet Gynecol Date: 2013-01-17 Impact factor: 8.661